Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Real-world (RW) use of fixed-duration (FD) ibrutinib+venetoclax (Ibr+Ven) in patients (pts) with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): Pooled analysis of REALITY-worldwide (WW) and REALITY-2 prospective cohort studies

Blood (2025) 146 (Supplement 1): 3903.

https://doi.org/10.1182/blood-2025-3903

Published: 2025

Journal Articles

Treatability with ibrutinib plus venetoclax in patients with CLL in the real-world. the eric international thrive study

Andrea Visentin, Thomas Chatzikonstantinou, Lydia Scarfo, Persefoni Talimtzi, Maria Angelopoulou, Tomas Arpas, Laura Ballotta, Leonidas Benetatos, Ana Margarida Bertolo, Horia Bumbea, Maurizio Cavallari, Anastasia Chatzidimitriou, Dominik Chraniuk, Anna Christoforidou, Francesca Cibien, Antonio Cuneo, Maria Ilaria del Principe, Marina Deodato, Enrico Derenzini, Michael Doubek, Fabiana Esposito, Lucia Farina, Gianmarco Favrin, Isacco Ferrarini, Annamaria Frustaci, Andrea Galitzia, Massimo Gentile, Iulia Roxana Iancu, Vanessa Innao, krzysztof jamroziak, Elzbieta Kalicinska, Maria Kislova, Ioannis Kyriakou, Luca Laurenti, Enrico Lista, Javier Loscertales, Alexandros Machairas, Giorgia Marcato, Francesca Martini, Nilla Maschio, Eva Minga, Riccardo Moia, Roberta Murru, Maura Nicolosi, Jacopo Olivieri, Carolina Pavlovsky, Miguel Pavlovsky, Sara Pepe, Ernesto Perez Persona, Giuseppe Petruzzellis, Gian Matteo Rigolin, Alessandro Sanna, Marina Siakantaris, Paolo Sportoletti, Oana Stanca, Niki Stavrogianni, Tamar Tadmor, Annamaria Tomasso, Marzia Varettoni, Theodoros Vassilakopoulos, Eva Gimeno Vazquez, Candida Vitale, Mohamed Yassin, Mihnea Zdrenghea, Klaudia Zielonka, Livio Trentin, Kostas Stamatopoulos, Paolo Ghia

Blood (2025) 146 (Supplement 1): 6287.

https://doi.org/10.1182/blood-2025-6287

Published: 2025

Journal Articles

Treatment with acalabrutinib in IGHV mutated setting and presence of splenomegaly are the main predictors of faster lymphocyte count decrease in CLL during monotherapy with cbtki

Blood (2025) 146 (Supplement 1): 7427.

https://doi.org/10.1182/blood-2025-7427

Published: 2025

Journal Articles

Acalabrutinib in High-Risk Chronic Lymphocytic Leukemia Patients Naïve or Previous Treated. a Multicenter Retrospective Observational Real-Life Experience

Blood (2024) 144 (Supplement 1): 6798.

https://doi.org/10.1182/blood-2024-203557

Published: 2024

Journal Articles

Baseline Characteristics from CLL-ZANU2024, an Italian Non-Interventional Study Assessing the Real-World Use of Zanubrutinib in the Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)

Enrica Antonia Martino, Raffaella Pasquale, Isacco Ferrarini, Riccardo Moia, Andrea Visentin, Alessandro Sanna, Marina Motta, Massimo Moratti, Paolo Sportoletti, Annalisa Chiarenza, Alessandro Maggi, Valentina Zammit, Michele Merli, Idanna Innocenti, Claudia Giordano, Laura Nocilli, Massimiliano Postorino, Caterina Stelitano, Andrea Ferrario, Annamaria Frustaci, Stefania Scardino, Paola Anticoli Borza, Laura Ballotta, Salvatrice Mancuso, Gerardo Musuraca, Anna Mele, Sara Galimberti, Gioacchino Catania, Annamaria Giordano, Ilaria Angeletti, Luana Schiattone, Elsa Pennese, Rosanna Miccolis, Angelo Fama, Giulio Giordano, Catello Califano, Ernesto Vigna, Antonella Bruzzese, Giuliana Farina, Pietro Bulian, Giacomo Loseto, Barbara Pocali, Vanessa Innao, Piero Galieni, Vincenzo Ludovico Fraticelli, Candida Vitale, Azzurra Anna Romeo, Marco Rossi, Ilaria Scortechini, Federico Vozzella, Luigi Malandruccolo, Enrico Derenzini, Valentina di Martina, Roberto Marasca, Maria Ilaria Del Principe, Marta Coscia, Nicola Di Renzo, Luca Laurenti, Antonino Neri, Pellegrino Musto, Francesco Di Raimondo, Alessandra Tedeschi, Livio Trentin, Gianluca Gaidano, Fortunato Morabito, Valter Gattei, Massimo Gentile

Blood (2024) 144 (Supplement 1): 6794.

https://doi.org/10.1182/blood-2024-205354

Published: 2024

Journal Articles

A Snapshot of the Management of Chronic Lymphocytic Leukemia in Italy. Preliminary Analysis on over 3000 Patients Enrolled in the Gimema CLL2121 Trial

Blood (2023) 142 (Supplement 1): 6544.

https://doi.org/10.1182/blood-2023-188454

Published: 2023

Journal Articles

Kinetics of Lymphocytosis during First-Line Treatment with BTK Covalent Inhibitors in Chronic Lymphocytic Leukemia Patients: An Italian Multicenter Experience of Real Life

Blood (2023) 142 (Supplement 1): 6545.

https://doi.org/10.1182/blood-2023-188941

Published: 2023

Journal Articles

Real-World Venetoclax-Obinutuzumab in 232 Treatment Naive CLL Patients: Feasibility and Tolerability

Blood (2023) 142 (Supplement 1): 4646.

https://doi.org/10.1182/blood-2023-186182

Published: 2023

Journal Articles

Efficacy and Safety of Ixazomib Induction and Maintenance in Newly Diagnosed Multiple Myeloma Patients According to the IMWG Frailty Score: A Post-Hoc Analysis of the EMN10-Unito Trial

Roberto Mina, MD, Alessandra Larocca, Massimo Offidani, Vanessa Innao, Claudia Cellini, Monica Galli, Giusy Cetani, Mariella Grasso, Giovannino Ciccone, Andrea Capra, Sara Aquino, Claudia Priola, Gloria Margiotta Casaluci, Giovanni De Sabbata, Stelvio Ballanti, Michele Cavo, Mario Boccadoro, Sara Bringhen, MD

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-136292

Published: 2020

Journal Articles

Efficacy and Safety of Ixazomib-Dexamethasone, Ixazomib-Cyclophosphamide-Dexamethasone, Ixazomib-Thalidomide-Dexamethasone and Ixazomib-Bendamustine-Dexamethasone for Elderly Newly Diagnosed Multiple Myeloma (NDMM) Patients: Analysis of the Phase II Randomized Unito-EMN10 Study

Blood (2019) 134 (Supplement_1): 3195.

https://doi.org/10.1182/blood-2019-124388

Published: 2019

Journal Articles

Tumor Circulating Plasma Cells Detected By Flow Cytometric Single Platform Method Correlate with Clinical Response to Therapy and Unfavorable Patients' Characteristics

Blood (2019) 134 (Supplement_1): 4357.

https://doi.org/10.1182/blood-2019-122657

Published: 2019

Journal Articles

Preliminary Results of a Prospective Observational Study to Assess the Prevalence of Gaucher Disease in an Adult Population Affected By MGUS

Gaetano Giuffrida, MD, Concetta Conticello, MD, Daniela Nicolosi, PharmD, Valeria Calafiore, Alessandra Romano, MD PhD, Ugo Consoli, MD, Caterina Musolino, MD, Vanessa Innao, Flavia Fiorenza, MD, Cinzia Maugeri, MD, Giuseppe Longo, MD, Maria Rocca Cingari, MD, Francesco Di Raimondo, MD

Blood (2019) 134 (Supplement_1): 4868.

https://doi.org/10.1182/blood-2019-129944

Published: 2019

Journal Articles

Impact of Cumulative Dose of Carfilzomib in Combination with Lenalidomide and Desamethasone in Relapsed Refractory Myeloma Patients: A Retrospective Real Life Survey of the Sicilian Myeloma Network

Blood (2018) 132 (Supplement 1): 5636.

https://doi.org/10.1182/blood-2018-99-116452

Published: 2018

Journal Articles

Reduced Dose-Intensity Subcutaneous Bortezomib Plus Prednisone (VP) Or Plus Cyclophosfamide (VCP) Or Plus Melphalan (VMP) For Newly Diagnosed Multiple Myeloma Patients Older Than 75 Years Of Age

Blood (2013) 122 (21): 539.

https://doi.org/10.1182/blood.V122.21.539.539

Published: 2013

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Real-world (RW) use of fixed-duration (FD) ibrutinib+venetoclax (Ibr+Ven) in patients (pts) with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): Pooled analysis of REALITY-worldwide (WW) and REALITY-2 prospective cohort studies

Treatability with ibrutinib plus venetoclax in patients with CLL in the real-world. the eric international thrive study

Treatment with acalabrutinib in IGHV mutated setting and presence of splenomegaly are the main predictors of faster lymphocyte count decrease in CLL during monotherapy with cbtki

Acalabrutinib in High-Risk Chronic Lymphocytic Leukemia Patients Naïve or Previous Treated. a Multicenter Retrospective Observational Real-Life Experience

Baseline Characteristics from CLL-ZANU2024, an Italian Non-Interventional Study Assessing the Real-World Use of Zanubrutinib in the Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)

A Snapshot of the Management of Chronic Lymphocytic Leukemia in Italy. Preliminary Analysis on over 3000 Patients Enrolled in the Gimema CLL2121 Trial

Kinetics of Lymphocytosis during First-Line Treatment with BTK Covalent Inhibitors in Chronic Lymphocytic Leukemia Patients: An Italian Multicenter Experience of Real Life

Real-World Venetoclax-Obinutuzumab in 232 Treatment Naive CLL Patients: Feasibility and Tolerability

Efficacy and Safety of Ixazomib Induction and Maintenance in Newly Diagnosed Multiple Myeloma Patients According to the IMWG Frailty Score: A Post-Hoc Analysis of the EMN10-Unito Trial

Efficacy and Safety of Ixazomib-Dexamethasone, Ixazomib-Cyclophosphamide-Dexamethasone, Ixazomib-Thalidomide-Dexamethasone and Ixazomib-Bendamustine-Dexamethasone for Elderly Newly Diagnosed Multiple Myeloma (NDMM) Patients: Analysis of the Phase II Randomized Unito-EMN10 Study

Tumor Circulating Plasma Cells Detected By Flow Cytometric Single Platform Method Correlate with Clinical Response to Therapy and Unfavorable Patients' Characteristics

Preliminary Results of a Prospective Observational Study to Assess the Prevalence of Gaucher Disease in an Adult Population Affected By MGUS

Impact of Cumulative Dose of Carfilzomib in Combination with Lenalidomide and Desamethasone in Relapsed Refractory Myeloma Patients: A Retrospective Real Life Survey of the Sicilian Myeloma Network

Reduced Dose-Intensity Subcutaneous Bortezomib Plus Prednisone (VP) Or Plus Cyclophosfamide (VCP) Or Plus Melphalan (VMP) For Newly Diagnosed Multiple Myeloma Patients Older Than 75 Years Of Age

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only